🟢 ProMIS Neurosciences is trading 12.8% up today on favorable interim Phase 1b data for Alzheimer’s drug PMN310

ProMIS Neurosciences is trading 12.8% up now at $12.88 after releasing favorable six-month interim data from its PRECISE-AD Phase 1b trial of Alzheimer’s drug PMN310.

• The company reported a strong safety profile with no ARIA-E and encouraging, directionally positive biomarker signals.
• Investor sentiment is further supported by a broader rally in biotech stocks amid sector M&A activity and positive clinical trial news across the industry.